Pricing Log in Create free account

Cullinan Therapeutics, Inc. (CGEM) vs Ginkgo Bioworks Holdings, Inc. (DNA)

Cullinan Therapeutics, Inc. and Ginkgo Bioworks Holdings, Inc. are both Biotechnology companies. Cullinan Therapeutics, Inc. and Ginkgo Bioworks Holdings, Inc. are of similar size ($695.0M and $670.7M). Cullinan Therapeutics, Inc. has the higher net margin (0.00% vs −260.0%) and the higher return on invested capital (0.00% vs −161.9%). Across the 12 metrics below, Cullinan Therapeutics, Inc. leads on 9 and Ginkgo Bioworks Holdings, Inc. on 3.

Valuation

Metric CGEM DNA Biotechnology median
P/E n/m n/m 10.60
P/S n/m 6.21 9.40
P/B 2.17 1.65 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 4.05 9.02
Earnings yield (27.34%) (44.77%) (32.88%)
Free cash flow yield (22.84%) (25.07%) (23.13%)

Profitability

Metric CGEM DNA Biotechnology median
Gross margin — 80.55% 68.51%
Operating margin 0.00% (273.61%) 0.00%
Net margin 0.00% (259.96%) 0.00%
Free cash flow margin 0.00% (155.75%) 0.00%
Return on equity (50.30%) (56.29%) (51.96%)
Return on assets (46.30%) (26.19%) (46.06%)
Return on invested capital 0.00% (161.94%) 0.00%

Growth

Metric CGEM DNA Biotechnology median
Revenue growth (TTM) — (51.54%) 6.76%
EPS growth (last fiscal year) (20.86%) 46.49% 29.88%
Revenue growth, 5-year CAGR — 17.29% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CGEM DNA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.42 4.57 4.97
Net debt to EBITDA 1.57 1.63 1.01

Dividend

Metric CGEM DNA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CGEM DNA Biotechnology median
Market cap 695.03m 670.71m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack